[go: up one dir, main page]

IL199891A - Aqueous compositions of (e)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzylsulfone for parenteral administration - Google Patents

Aqueous compositions of (e)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzylsulfone for parenteral administration

Info

Publication number
IL199891A
IL199891A IL199891A IL19989109A IL199891A IL 199891 A IL199891 A IL 199891A IL 199891 A IL199891 A IL 199891A IL 19989109 A IL19989109 A IL 19989109A IL 199891 A IL199891 A IL 199891A
Authority
IL
Israel
Prior art keywords
methoxybenzylsulfone
trimethoxystyryl
carboxymethylamino
parenteral administration
aqueous compositions
Prior art date
Application number
IL199891A
Other languages
Hebrew (he)
Other versions
IL199891A0 (en
Original Assignee
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconova Therapeutics Inc filed Critical Onconova Therapeutics Inc
Publication of IL199891A0 publication Critical patent/IL199891A0/en
Publication of IL199891A publication Critical patent/IL199891A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL199891A 2007-01-16 2009-07-16 Aqueous compositions of (e)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzylsulfone for parenteral administration IL199891A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88037607P 2007-01-16 2007-01-16
PCT/US2008/000523 WO2008088803A2 (en) 2007-01-16 2008-01-16 Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones

Publications (2)

Publication Number Publication Date
IL199891A0 IL199891A0 (en) 2010-04-15
IL199891A true IL199891A (en) 2016-05-31

Family

ID=39636568

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199891A IL199891A (en) 2007-01-16 2009-07-16 Aqueous compositions of (e)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzylsulfone for parenteral administration

Country Status (7)

Country Link
US (1) US8476320B2 (en)
EP (1) EP2124569A4 (en)
JP (1) JP2010515772A (en)
KR (1) KR20090114398A (en)
CA (1) CA2675374C (en)
IL (1) IL199891A (en)
WO (1) WO2008088803A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4982364B2 (en) * 2004-07-19 2012-07-25 オンコノバ セラピューティクス インコーポレイテッド (E) -2,6-dialkyloxystyryl 4-substituted benzyl sulfone preparations for parenteral administration
MX2012010935A (en) 2010-03-26 2012-12-10 Onconova Therapeutics Inc Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlo robenzyl sulfone.
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
EP2928456B1 (en) 2012-12-07 2021-02-03 Onconova Therapeutics, Inc. Treatment of hematological cancer refractory to an anti-cancer agent
WO2015074281A1 (en) * 2013-11-25 2015-05-28 杭州普晒医药科技有限公司 Rigosertib salt, crystal form thereof, and their preparation method and application
WO2017023912A1 (en) * 2015-08-03 2017-02-09 Temple University - Of The Commonwealth System Of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
US12156856B2 (en) 2017-04-13 2024-12-03 Traws Pharma, Inc. Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
UY37380A (en) * 2017-04-13 2018-10-31 Onconova Therapeutics Inc FORMULATIONS WITH GREATER STABILITY AND BIODISPONIBILITY FOR ADMINISTRATION OF (E) -2,6-DIALCOXIESTIRIL BENCILSULPHONES REPLACED IN 4
US11382877B2 (en) 2017-04-13 2022-07-12 Onconova Therapeutics, Inc. Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
CN109232403A (en) * 2017-07-10 2019-01-18 亚宝药业集团股份有限公司 Amides prodrug derivant as kinases inhibitor
EP3764991A4 (en) * 2018-03-13 2022-12-07 Capsular Technologies Pty Ltd. Vaccine composition
US11981624B2 (en) * 2018-10-26 2024-05-14 Teva Pharmaceuticals International Gmbh Crystalline polymorphs of Rigosertib Sodium
CN114539110B (en) * 2020-11-26 2023-02-14 东南大学 HDAC inhibitor containing RAS/RAF protein interfering group and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487428B1 (en) * 2002-02-28 2011-09-21 Temple University - Of The Commonwealth System of Higher Education Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
JP4982364B2 (en) * 2004-07-19 2012-07-25 オンコノバ セラピューティクス インコーポレイテッド (E) -2,6-dialkyloxystyryl 4-substituted benzyl sulfone preparations for parenteral administration

Also Published As

Publication number Publication date
EP2124569A4 (en) 2013-02-27
US8476320B2 (en) 2013-07-02
US20100152096A1 (en) 2010-06-17
CA2675374A1 (en) 2008-07-24
IL199891A0 (en) 2010-04-15
JP2010515772A (en) 2010-05-13
KR20090114398A (en) 2009-11-03
WO2008088803A2 (en) 2008-07-24
CA2675374C (en) 2014-03-04
EP2124569A2 (en) 2009-12-02
WO2008088803A3 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
IL199891A (en) Aqueous compositions of (e)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzylsulfone for parenteral administration
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
IL201973A0 (en) 3,3-spiroindolinone derivatives
DK3872058T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
EP2361902A4 (en) 4,6-diaminonicotinamide compound
SI2344465T1 (en) Crystalline forms of (r) -5- š3-chloro-4-( 2, 3-dihydroxy-propoxy)-benz šzćylideneć-2- šzć-propylimino) -3-o-tolyl-thiazolidin-4-one
ZA201104706B (en) Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
EP2325175A4 (en) 2,4-diaminopyrimidine compound
IL208203A (en) 2,3-dihydro-pyrido-1,4-oxazine and 2,3-dihydro-4-oxa-1,9-diazaphenanthrene derivatives, processes for their preparation and pharmaceutical compositions comprising them
ZA200809800B (en) 2-Thioxanthine derivatives acting as Mpo-inhibitors
ZA201005383B (en) Substituted arylamide ozazepinopyrimidone derivatives
EP2223929A4 (en) Gambogic glycoside derivatives and analogs, the preparation and the application thereof
ZA201008657B (en) 4,5-dihydro-oxazol-2-yl derivatives
ZA200908612B (en) 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
ZA201002217B (en) 1,3-dihydroisoindole derivatives
SI2513119T1 (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-š4,3-cćisoquinoline derivatives
EP2202231A4 (en) 2,3-dihydroiminoisoindole derivative
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
EP2250145A4 (en) Preparation of naphthoquinone compounds using 2, 3-dihalonapthoquinone
SI2225232T1 (en) Process for the preparation of substituted 1,3-oxathiolanes
PL2099765T3 (en) 5, 6, or 7-substituted-3-arylisoquinolinamine derivatives as antitumor agents
EP1996192A4 (en) Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones
IL201444A0 (en) New 4, 8 - diphenyl - polyazanaphthalene derivatives
ZA201005346B (en) 3,8-diaminotetrahydroquinoline derivative

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed